Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00549328 · ClinicalTrials.gov registry record · Phase 2
Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00549328 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 14 participants.
The verdict
NCT00549328, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study is designed to evaluate the efficacy and safety of monotherapy pazopanib (a small molecule tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGF, and c-kit) in subjects with advanced (Stage IIIB or IV) non-small cell lung cancer.
Interventions
- DRUG Pazopanib (GW786034)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00549328
The ClinicalTrials.gov registry entry for NCT00549328 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pazopanib (GW786034) is the first listed.
NCT00549328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00549328 about?
NCT00549328 is a clinical study titled "Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer". This study is designed to evaluate the efficacy and safety of monotherapy pazopanib (a small molecule tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGF, and c-kit) in subjects with advanced (Stage IIIB or IV) non-small cell lung cancer.
What is the current status of trial NCT00549328?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2008-02. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00549328?
The interventions under investigation include: Pazopanib (GW786034) (DRUG).
Who is sponsoring clinical trial NCT00549328?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.